Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 57

Publication Record


ER trapping reveals Golgi enzymes continually revisit the ER through a recycling pathway that controls Golgi organization.
Sengupta P, Satpute-Krishnan P, Seo AY, Burnette DT, Patterson GH, Lippincott-Schwartz J
(2015) Proc Natl Acad Sci U S A 112: E6752-61
MeSH Terms: Animals, COS Cells, Cercopithecus aethiops, Endoplasmic Reticulum, Golgi Apparatus, HeLa Cells, Humans, Mitosis, Phospholipases A2, Calcium-Independent, Sirolimus, Tacrolimus Binding Protein 1A, Tacrolimus Binding Proteins, rab GTP-Binding Proteins
Show Abstract · Added August 25, 2017
Whether Golgi enzymes remain localized within the Golgi or constitutively cycle through the endoplasmic reticulum (ER) is unclear, yet is important for understanding Golgi dependence on the ER. Here, we demonstrate that the previously reported inefficient ER trapping of Golgi enzymes in a rapamycin-based assay results from an artifact involving an endogenous ER-localized 13-kD FK506 binding protein (FKBP13) competing with the FKBP12-tagged Golgi enzyme for binding to an FKBP-rapamycin binding domain (FRB)-tagged ER trap. When we express an FKBP12-tagged ER trap and FRB-tagged Golgi enzymes, conditions precluding such competition, the Golgi enzymes completely redistribute to the ER upon rapamycin treatment. A photoactivatable FRB-Golgi enzyme, highlighted only in the Golgi, likewise redistributes to the ER. These data establish Golgi enzymes constitutively cycle through the ER. Using our trapping scheme, we identify roles of rab6a and calcium-independent phospholipase A2 (iPLA2) in Golgi enzyme recycling, and show that retrograde transport of Golgi membrane underlies Golgi dispersal during microtubule depolymerization and mitosis.
0 Communities
1 Members
0 Resources
13 MeSH Terms
Assessment of arterial stiffness using pulse wave velocity in tacrolimus users the first year post kidney transplantation: a prospective cohort study.
Birdwell KA, Jaffe G, Bian A, Wu P, Ikizler TA
(2015) BMC Nephrol 16: 93
MeSH Terms: Adult, Age Factors, Aorta, Diabetes Mellitus, Female, Humans, Immunosuppressive Agents, Kidney Transplantation, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Pulse Wave Analysis, Tacrolimus, Vascular Stiffness
Show Abstract · Added August 5, 2015
BACKGROUND - The leading cause of death in end stage renal disease is cardiovascular disease (CVD). Kidney transplantation is associated with improved survival over dialysis. We hypothesized that arterial stiffness, a marker of CVD, would improve in patients post kidney transplant, potentially explaining one mechanism of survival benefit from transplant.
METHODS - After obtaining Institutional Review Board approval and informed consent, we performed a longitudinal prospective cohort study of 66 newly transplanted adult kidney transplant recipients, using aortic pulse wave velocity (PWV) to assess arterial stiffness over a 12 month period. All patients were assessed within one month of transplant (baseline) and 12 months post transplant. The primary outcome was change in PWV score at 12 months which we assessed using Wilcoxon Signed Rank test. Secondary analyses included correlation of predictors with PWV score at both time points.
RESULTS - The median age of the cohort was 49.7 years at transplant, with 27 % Black and 27 % female. At baseline, 43 % had tobacco use, 30 % had a history of CVD, and 42 % had diabetes. Median baseline calcium was 9.1 mg/dL and median phosphorus was 5.1 mg/dL. Median PWV score was 9.25 and 8.97 m/s at baseline versus month 12, respectively, showing no significant change (median change of -0.07, p = 0.7). In multivariable regression, subjects with increased age at transplant (p = 0.008), diabetes (p = 0.002), and a higher baseline PWV score (p < 0.001) were at increased risk of having a high PWV score 12 months post transplant.
CONCLUSION - Aortic arterial stiffness does not progress in the first year post kidney transplant. Increasing age, diabetes, and higher baseline PWV score identify patients at risk for increased arterial stiffness. Further research that assesses patients for greater than one year and includes a control dialysis group would be helpful in further understanding the change in arterial stiffness post transplantation.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Pharmacogenomics: personalizing pediatric heart transplantation.
Van Driest SL, Webber SA
(2015) Circulation 131: 503-12
MeSH Terms: Child, Heart Diseases, Heart Transplantation, Humans, Pediatrics, Pharmacogenetics, Precision Medicine, TOR Serine-Threonine Kinases, Tacrolimus
Added April 11, 2017
0 Communities
1 Members
0 Resources
9 MeSH Terms
A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances.
Nedelcovych MT, Gould RW, Zhan X, Bubser M, Gong X, Grannan M, Thompson AT, Ivarsson M, Lindsley CW, Conn PJ, Jones CK
(2015) ACS Chem Neurosci 6: 485-93
MeSH Terms: Analysis of Variance, Animals, Brain Waves, Corticosterone, Disease Models, Animal, Electroencephalography, Electromyography, Fourier Analysis, Indoles, Male, Neuropeptide Y, RNA, Messenger, Random Allocation, Rats, Rats, Sprague-Dawley, Serotonin, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, Tacrolimus Binding Proteins, Time Factors
Show Abstract · Added February 12, 2015
Hyperarousal and sleep disturbances are common, debilitating symptoms of post-traumatic stress disorder (PTSD). PTSD patients also exhibit abnormalities in quantitative electroencephalography (qEEG) power spectra during wake as well as rapid eye movement (REM) and non-REM (NREM) sleep. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for PTSD, provide modest remediation of the hyperarousal symptoms in PTSD patients, but have little to no effect on the sleep-wake architecture deficits. Development of novel therapeutics for these sleep-wake architecture deficits is limited by a lack of relevant animal models. Thus, the present study investigated whether single prolonged stress (SPS), a rodent model of traumatic stress, induces PTSD-like sleep-wake and qEEG spectral power abnormalities that correlate with changes in central serotonin (5-HT) and neuropeptide Y (NPY) signaling in rats. Rats were implanted with telemetric recording devices to continuously measure EEG before and after SPS treatment. A second cohort of rats was used to measure SPS-induced changes in plasma corticosterone, 5-HT utilization, and NPY expression in brain regions that comprise the neural fear circuitry. SPS caused sustained dysregulation of NREM and REM sleep, accompanied by state-dependent alterations in qEEG power spectra indicative of cortical hyperarousal. These changes corresponded with acute induction of the corticosterone receptor co-chaperone FK506-binding protein 51 and delayed reductions in 5-HT utilization and NPY expression in the amygdala. SPS represents a preclinical model of PTSD-related sleep-wake and qEEG disturbances with underlying alterations in neurotransmitter systems known to modulate both sleep-wake architecture and the neural fear circuitry.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Structure of human peptidyl-prolyl cis-trans isomerase FKBP22 containing two EF-hand motifs.
Boudko SP, Ishikawa Y, Nix J, Chapman MS, Bächinger HP
(2014) Protein Sci 23: 67-75
MeSH Terms: Catalytic Domain, EF Hand Motifs, Ehlers-Danlos Syndrome, Endoplasmic Reticulum, Humans, Hydrophobic and Hydrophilic Interactions, Models, Molecular, Mutation, Peptidylprolyl Isomerase, Protein Conformation, Protein Multimerization, Protein Structure, Secondary, Protein Structure, Tertiary, Tacrolimus Binding Proteins
Show Abstract · Added November 2, 2017
The FK506-binding protein (FKBP) family consists of proteins with a variety of protein-protein interaction domains and versatile cellular functions. It is assumed that all members are peptidyl-prolyl cis-trans isomerases with the enzymatic function attributed to the FKBP domain. Six members of this family localize to the mammalian endoplasmic reticulum (ER). Four of them, FKBP22 (encoded by the FKBP14 gene), FKBP23 (FKBP7), FKBP60 (FKBP9), and FKBP65 (FKBP10), are unique among all FKBPs as they contain the EF-hand motifs. Little is known about the biological roles of these proteins, but emerging genetics studies are attracting great interest to the ER resident FKBPs, as mutations in genes encoding FKBP10 and FKBP14 were shown to cause a variety of matrix disorders. Although the structural organization of the FKBP-type domain as well as of the EF-hand motif has been known for a while, it is difficult to conclude how these structures are combined and how it affects the protein functionality. We have determined a unique 1.9 Å resolution crystal structure for human FKBP22, which can serve as a prototype for other EF hand-containing FKBPs. The EF-hand motifs of two FKBP22 molecules form a dimeric complex with an elongated and predominantly hydrophobic cavity that can potentially be occupied by an aliphatic ligand. The FKBP-type domains are separated by a cleft and their putative active sites can catalyze isomerazation of two bonds within a polypeptide chain in extended conformation. These structural results are of prime interest for understanding biological functions of ER resident FKBPs containing EF-hand motifs.
© 2013 The Protein Society.
0 Communities
1 Members
0 Resources
14 MeSH Terms
False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review.
Taguchi K, Ohmura T, Ohya Y, Horio M, Furukawa K, Jono H, Inomata Y, Saito H
(2014) Exp Clin Transplant 12: 474-8
MeSH Terms: Aged, Drug Monitoring, False Positive Reactions, Female, Humans, Immunoassay, Immunosuppressive Agents, Liver Transplantation, Magnetics, Middle Aged, Predictive Value of Tests, Reproducibility of Results, Tacrolimus, Time Factors, Treatment Outcome
Show Abstract · Added February 11, 2015
Safe use of tacrolimus relies on regular whole-blood drug monitoring. Of the methods used to assess whole-blood tacrolimus concentration, antibody-conjugated magnetic immunoassay is mostly used for therapeutic drug monitoring because it requires only a minimal sample preparation and no pretreatment procedure. However, several cases recently have been reported in which abnormally false elevated tacrolimus concentrations were measured by antibody-conjugated magnetic immunoassay (>15 ng/mL), despite the absence of clinical symptoms. We present 2 cases of falsely detected tacrolimus concentrations that did not show abnormally high values within the therapeutic range. Whole-blood tacrolimus concentrations obtained by antibody-conjugated magnetic immunoassay showed well-controlled concentrations (approximately 2-8 ng/mL), whereas those obtained by another immunoassay and in washed erythrocytes were below the assay range (< 1.2 ng/mL). Thus, antibody-conjugated magnetic immunoassay can elicit falsely positive results of tacrolimus concentrations, even though they are within the therapeutic range.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes.
Rickels MR, Kong SM, Fuller C, Dalton-Bakes C, Ferguson JF, Reilly MP, Teff KL, Naji A
(2013) J Clin Endocrinol Metab 98: E1780-5
MeSH Terms: Adult, Diabetes Mellitus, Type 1, Female, Glucose Clamp Technique, Glycated Hemoglobin A, Graft Rejection, Humans, Immunosuppressive Agents, Insulin, Insulin Resistance, Islets of Langerhans Transplantation, Liver, Male, Middle Aged, Muscle, Skeletal, Sirolimus, Tacrolimus
Show Abstract · Added January 20, 2015
CONTEXT - Islet transplantation can improve metabolic control for type 1 diabetes (T1D), an effect anticipated to improve insulin sensitivity. However, current immunosuppression regimens containing tacrolimus and sirolimus have been shown to induce insulin resistance in rodents.
OBJECTIVE - The objective of the study was to evaluate the effect of islet transplantation on insulin sensitivity in T1D using euglycemic clamps with the isotopic dilution method to distinguish between effects at the liver and skeletal muscle.
DESIGN, SETTING, AND PARTICIPANTS - Twelve T1D subjects underwent evaluation in the Clinical and Translational Research Center before and between 6 and 7 months after the transplant and were compared with normal control subjects.
INTERVENTION - The intervention included intrahepatic islet transplantation according to a Clinical Islet Transplantation Consortium protocol under low-dose tacrolimus and sirolimus immunosuppression.
MAIN OUTCOME MEASURES - Total body (M/Δinsulin), hepatic (1/endogenous glucose production ·basal insulin) and peripheral [(Rd - endogenous glucose production)/Δinsulin] insulin sensitivity assessed by hyperinsulinemic (1 mU·kg(-1)·min(-1)) euglycemic (∼90 mg/dL) clamps with 6,6-(2)H2-glucose tracer infusion were measured.
RESULTS - Glycosylated hemoglobin was reduced in the transplant recipients from 7.0% ± 0.3% to 5.6% ± 0.1% (P < .01). There were increases in total (0.11 ± 0.01 to 0.15 ± 0.02 dL/min·kg per microunit per milliliter), hepatic [2.3 ± 0.1 to 3.7 ± 0.4 × 10(2) ([milligrams per kilogram per minute](-1)·(microunits per milliliter)(-1))], and peripheral (0.08 ± 0.01 to 0.12 ± 0.02 dL/min·kg per microunit per milliliter) insulin sensitivity from before to after transplantation (P < .05 for all). All insulin sensitivity measures were less than normal in T1D before (P ≤ .05) and not different from normal after transplantation.
CONCLUSIONS - Islet transplantation results in improved insulin sensitivity mediated by effects at both the liver and skeletal muscle. Modern dosing of glucocorticoid-free immunosuppression with low-dose tacrolimus and sirolimus does not induce insulin resistance in this population.
0 Communities
1 Members
0 Resources
17 MeSH Terms
Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.
Langone A, Doria C, Greenstein S, Narayanan M, Ueda K, Sankari B, Pankewycz O, Shihab F, Chan L
(2013) Clin Transplant 27: 15-24
MeSH Terms: Adult, Antibiotics, Antineoplastic, Female, Follow-Up Studies, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Kidney Function Tests, Kidney Transplantation, Male, Middle Aged, Mycophenolic Acid, Postoperative Complications, Prognosis, Prospective Studies, Registries, Tacrolimus
Show Abstract · Added March 19, 2014
Prospective data are lacking concerning the effect of reduced mycophenolic acid (MPA) dosing on efficacy and the influence of concomitant tacrolimus exposure. The Mycophenolic Renal Transplant (MORE) Registry is a prospective, observational study of de novo kidney transplant patients receiving MPA therapy under routine management. The effect of MPA dose reduction, interruption, or discontinuation (dose changes) was assessed in 870 tacrolimus-treated patients: 375 (43.1%) reduced tacrolimus (≤ 7 ng/mL at baseline) and 495 (56.9%) standard tacrolimus (>7 ng/mL); enteric-coated mycophenolate sodium 589 (67.7%) and mycophenolate mofetil 281 (32.3%). During baseline to month 1, months 1-3, months 3-6, and months 6-12, 9.3% (78/838), 16.6% (132/794), 20.7% (145/701), and 13.1% (70/535) patients, respectively, required MPA dose changes. These patients experienced an increased risk of biopsy-proven acute rejection at one yr with tacrolimus exposure either included in the model (hazard ratio [HR] 2.60, 95% CI 1.28-5.29, p = 0.008) or excluded (HR 2.58, 95% CI 1.28-5.23, p = 0.008). MPA dose changes were significantly associated with one yr graft failure when tacrolimus exposure was included (HR 2.23; 95% CI 1.01-4.89, p = 0.047) but not when tacrolimus exposure was excluded (HR 2.16; 95% CI 0.99-4.79; p = 0.054). These results suggest that reducing or discontinuing MPA can adversely affect graft outcomes regardless of tacrolimus trough levels.
© 2012 John Wiley & Sons A/S.
0 Communities
1 Members
0 Resources
18 MeSH Terms
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW
(2012) Pharmacogenet Genomics 22: 32-42
MeSH Terms: ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1, Adult, Age Factors, Body Weight, Cytochrome P-450 CYP3A, Databases, Nucleic Acid, Dose-Response Relationship, Drug, Drug Monitoring, Electronic Health Records, Female, Genetic Association Studies, Genotype, Hemoglobins, Humans, Immunosuppressive Agents, Kidney Transplantation, Linkage Disequilibrium, Male, Middle Aged, Polymorphism, Single Nucleotide, Pregnane X Receptor, Receptors, Steroid, Tacrolimus
Show Abstract · Added December 10, 2013
OBJECTIVE - Tacrolimus, an immunosuppressive drug widely prescribed in kidney transplantation, requires therapeutic drug monitoring due to its marked interindividual pharmacokinetic variability and narrow therapeutic index. Previous studies have established that CYP3A5 rs776746 is associated with tacrolimus clearance, blood concentration, and dose requirement. The importance of other drug absorption, distribution, metabolism, and elimination (ADME) gene variants has not been well characterized.
METHODS - We used novel DNA biobank and electronic medical record resources to identify ADME variants associated with tacrolimus dose requirement. Broad ADME genotyping was performed on 446 kidney transplant recipients, who had been dosed to a steady state with tacrolimus. The cohort was obtained from Vanderbilt's DNA biobank, BioVU, which contains linked deidentified electronic medical record data. Genotyping included Affymetrix drug-metabolizing enzymes and transporters Plus (1936 polymorphisms), custom Sequenom Massarray iPLEX Gold assay (95 polymorphisms), and ancestry-informative markers. The primary outcome was tacrolimus dose requirement defined as blood concentration to dose ratio.
RESULTS - In analyses, which adjusted for race and other clinical factors, we replicated the association of tacrolimus blood concentration to dose ratio with CYP3A5 rs776746 (P=7.15×10), and identified associations with nine variants in linkage disequilibrium with rs776746, including eight CYP3A4 variants. No NR1I2 variants were significantly associated. Age, weight, and hemoglobin were also significantly associated with the outcome. In final models, rs776746 explained 39% of variability in dose requirement and 46% was explained by the model containing clinical covariates.
CONCLUSION - This study highlights the utility of DNA biobanks and electronic medical records for tacrolimus pharmacogenomic research.
0 Communities
6 Members
0 Resources
24 MeSH Terms
Castleman disease in a pediatric liver transplant recipient: a case report and literature review.
Bonatti HJ, Axt J, Hunter EB, Lott SL, Frangoul H, Gillis L, Correa H, Kelly B
(2012) Pediatr Transplant 16: E229-34
MeSH Terms: Adolescent, Adult, Antigens, CD20, B-Lymphocytes, CD3 Complex, Castleman Disease, Graft Survival, Herpesvirus 8, Human, Humans, Immunosuppressive Agents, Infant, Newborn, Liver Failure, Liver Transplantation, Lymphatic Diseases, Male, Middle Aged, Polymerase Chain Reaction, Sirolimus, Splenomegaly, T-Lymphocytes, Tacrolimus, Tomography, X-Ray Computed
Show Abstract · Added March 27, 2014
Castleman disease is a rare hematologic disorder, closely linked to the HHV-8, and most commonly observed in immunocompromised individuals. Thirteen months following a liver transplant for CPS-1 defect, a 15-month-old boy presented with fevers, anemia, and growth retardation. Abdominal CT scan showed splenomegaly and generalized lymphadenopathy. Histology of chest wall lymph nodes revealed a mixed CD3+ T-cell and CD20+ B-cell population with atretic germinal centers consistent with multicentric Castleman disease. Qualitative DNA PCR detected HHV-8 in the resected lymph node and in the blood, supporting the diagnosis. Immunosuppression was tapered, and he was transitioned from tacrolimus to sirolimus. His graft function remained stable, and repeat imaging showed regression of the lymphadenopathy. The child is living one yr after Castleman disease diagnosis with a well-functioning graft. Castleman disease is a potential complication of solid organ transplant and HHV-8 infection. Reduction in immunosuppression and switch to sirolimus may be an effective strategy to treat this condition.
© 2011 John Wiley & Sons A/S.
0 Communities
1 Members
0 Resources
22 MeSH Terms